ArticleJournal of clinical medicine2022
Time-Averaged Hematuria as a Prognostic Indicator of Renal Outcome in Patients with IgA Nephropathy.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of hematuria on long term kidney outcomes in adults with immunoglobulin A nephropathy: a systematic literature review and meta-analysis.Frontiers in nephrology · 2026Pooled it
- Association Between Surrogate Endpoints and Clinical Outcomes in Immunoglobulin A Nephropathy: A Systematic Literature Review.Advances in therapy · 2025Pooled it
- Chronic kidney disease progression in glomerular diseases: is hematuria a key risk factor?Pediatric nephrology (Berlin, Germany) · 2026Review
- Systematic Review of Persistent Microscopic Hematuria and Kidney Outcomes in IgAN.Kidney international reports · 2026Article
- Remission of hematuria is associated with a better prognosis in immunoglobulin A nephropathy.Kidney research and clinical practice · 2026Article
- Microscopic hematuria as a marker of glomerular injury rather than a direct cause of kidney damage.Pediatric nephrology (Berlin, Germany) · 2026Article
- Time-Updated Hematuria and Kidney Disease Progression in IgAN.Kidney international reports · 2026Article
- Microscopic hematuria in IgA nephropathy: a biomarker of disease activity.Clinical kidney journal · 2026Review
- Principles for Optimal Drug Selection in IgA Nephropathy-Time for Integrating Pathogenesis and Clinical Markers to Guide Therapy.Nephrology (Carlton, Vic.) · 2026Review
- Real-world multicenter evidence on Nefecon for attenuating proteinuria and kidney function decline in IgA nephropathy.Frontiers in immunology · 2026Observational
- Pandemic and post-pandemic shifts in onset and severity of pediatric nephrotic syndrome: a comparative cohort analysis.Frontiers in immunology · 2026Article
- Prognostic relevance of persistent haematuria in patients with lupus nephritis.Clinical kidney journal · 2026Article
- The ratio of high aspartate aminotransferase to alanine aminotransferase: an independent risk factor associated with poor prognosis in IgA nephropathy.Clinical and experimental nephrology · 2024Article
- Differences of clinicopathological characteristics and outcomes of IgA nephropathy patients with and without nephrotic syndrome.International urology and nephrology · 2024Article
- Blood and urine biomarkers of disease progression in IgA nephropathy.Biomarker research · 2024Review
- Contemporary review of IgA nephropathy.Frontiers in immunology · 2024Review
- Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients.Clinical kidney journal · 2023Review
- Current and Future Therapeutical Options in Alport Syndrome.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
We aim to investigate the association of time-averaged hematuria (TA-hematuria) with the progression of IgA nephropathy (IgAN). Based on TA-hematuria during follow-up, 152 patients with IgAN were divided into a hematuria remission group (≤28 red blood cells [RBCs]/μL) and a persistent hematuria group (>28 RBCs/μL). The persistent hematuria group had a higher percentage of patients with macroscopic hematuria, lower levels of hemoglobin and TA-serum albumin, and more severe renal pathologic lesions. The composite endpoint is defined as a doubling of the baseline SCr level (D-SCr), or the presence of ESRD. During the mean follow-up of 58.08 ± 23.51 months, 15 patients (9.9%) reached the primary outcome of ESRD and 19 patients (12.5%) reached the combined renal endpoint. Kaplan-Meier analysis showed that the persistent hematuria group had a lower renal survival rate. The persistent hematuria patients who were incorporated with proteinuria (≥1.0 g/day) and low TA-serum albumin (<40 g/L) had the worst renal outcomes. Multivariate Cox regression indicated that TA-hematuria (hazard ratio [HR] = 0.004, 95% CI: 0.001, 0.008; p = 0.010) was independently associated with the progression of IgAN. Receiver operating characteristic analysis indicated the optimal TA-hematuria cutoff value for predicting the progression of IgAN was 201.21 RBCs/μL in females and 37.25 RBCs/μL in males.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.